Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

(Former name or former address, if changed since last report.)

(Exact Name of Registrant as Specified in Its Charter)

Item 5.07. Submission of Matters to a Vote to Security Holders

BioPharmX Corporation (the “ Company ”) held a Special Meeting of Stockholders on March 28, 2017 (the “ Special Meeting ”). As of the close of business on February 15, 2017, the record date for the Special Meeting, 67,719,577 shares of common stock were outstanding and entitled to vote. Present at the Special Meeting in person or by proxy were holders representing 58,762,791 shares of common stock, representing 86.8% of the eligible votes, constituting a quorum.

Voting results were as follows:

Proposal 1 : To approve an amendment to our certificate of incorporation to increase the total number of authorized shares of common stock from 90,000,000 shares to 450,000,000 shares (the “ Authorized Share Increase Proposal ”):

For Against Abstain 50,103,622 8,540,586 118,583

Proposal 2 : To approve an amendment to our certificate of incorporation to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-25, with the exact ratio to be set within that range at the discretion of our board of directors before January 31, 2018 without further approval or authorization of our stockholders (the “ Reverse Split Proposal ”). The board of directors may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion:

For Against Abstain 44,849,162 13,794,969 118,660

Proposal 3 : Contingent upon (i) the approval of the Authorized Share Increase Proposal or (ii) the Reverse Split Proposal and the Board’s subsequent determination to effect the reverse split, to approve the amendment of our 2016 Equity Incentive Plan such that the number of shares available for issuance thereunder will increase by 20,000,000 shares on a pre-split basis (the “ Plan Increase Proposal ”):

For Against Abstain Broker Non-Votes 33,085,877 10,618,706 50,814 15,007,394